Scholarlink

Introduction <p> The efficacy and safety of high-dose rifampicin in patients with tuberculous meningitis (TBM) remain uncertain.</p> Method <p> A&#xa0;comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Database was conducted&#xa0;to identify randomized controlled trials (RCTs) evaluating&#xa0;the efficacy and safety of high-dose rifampicin treatment in patients with TBM, up to October 8, 2024.&#xa0;The primary outcome was all-cause mortality at the longest follow-up period reported by individual trials, while the secondary outcome was the incidence of serious adverse events. We applied a random-effects model&#xa0;and calculated risk ratios (RR) with 95% confidence intervals (CIs)&#xa0;of pooled outcomes.</p> Result <p> Seven RCTs involving 1,296 TBM patients were included. High-dose rifampicin did not reduce all-cause mortality (RR = 0.88, 95% CI: 0.55–1.43,<i>P</i>= 0.61). Similarly, it was not associated with a reduction in serious adverse events (RR = 0.96, 95% CI: 0.62–1.50,<i>P</i>= 0.87).</p> Conclusion <p>This meta-analysis of seven RCTs involving 1,296 patients with TBM found that high-dose rifampicin treatment neither significantly reduced all-cause mortality nor decreased serious adverse events.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High dose of rifampicin in the treatment of tuberculous meningitis: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年1月9日

查看全文
  • Jiaqi Pu,
  • Shouquan Wu,
  • Jian-Qing He

摘要

Introduction

The efficacy and safety of high-dose rifampicin in patients with tuberculous meningitis (TBM) remain uncertain.

Method

A comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Database was conducted to identify randomized controlled trials (RCTs) evaluating the efficacy and safety of high-dose rifampicin treatment in patients with TBM, up to October 8, 2024. The primary outcome was all-cause mortality at the longest follow-up period reported by individual trials, while the secondary outcome was the incidence of serious adverse events. We applied a random-effects model and calculated risk ratios (RR) with 95% confidence intervals (CIs) of pooled outcomes.

Result

Seven RCTs involving 1,296 TBM patients were included. High-dose rifampicin did not reduce all-cause mortality (RR = 0.88, 95% CI: 0.55–1.43,P= 0.61). Similarly, it was not associated with a reduction in serious adverse events (RR = 0.96, 95% CI: 0.62–1.50,P= 0.87).

Conclusion

This meta-analysis of seven RCTs involving 1,296 patients with TBM found that high-dose rifampicin treatment neither significantly reduced all-cause mortality nor decreased serious adverse events.